Page 69 - Read Online

15. Edeline J, Crouzet L, Le Sourd S, Larible C, Brunot A, Le Roy F, discontinuation and lower survival rates are likely in elderly Japanese
Cattenoz C, Latournerie M, Gédouin D, Guillygomarc’h A, Boucher E. patients with advanced hepatocellular carcinoma receiving sorafenib.
Sorafenib use in elderly patients with hepatocellular carcinoma: Hepatol Res 2011;41:296-302.
Caution about use of platelet aggregation inhibitors. Cancer Chemother 20. Wong H, Tang YF, Yao TJ, Chiu J, Leung R, Chan P, Cheung TT,
Pharmacol 2015;75:215-9. Chan AC, Pang RW, Poon R, Fan ST, Yau T. The outcomes and safety of
16. Jo M, Yasui K, Kirishima T, Shima T, Niimi T, Katayama T, Mori T, single-agent sorafenib in the treatment of elderly patients with advanced
Funaki J, Sumida Y, Fujii H, Takami S, Kimura H, Mitsumoto Y, hepatocellular carcinoma (HCC). Oncologist 2011;16:1721-8.
Minami M, Yamaguchi K, Yoshinami N, Mizuno M, Sendo R, Tanaka S, 21. Germano D, Tinessa V, Barletta E, Cannella L, Daniele B. Targeted
Shintani H, Kagawa K, Okanoue T, Itoh Y. Effi cacy and safety of therapy for advanced hepatocellular cancer in the elderly: focus on
sorafenib in very elderly patients aged 80 years and older with advanced sorafenib. Drugs Aging 2013;30:887-92.
hepatocellular carcinoma. Hepatol Res 2014;44:1329-38. 22. Cabibbo G, Maida M, Cammà C, Craxì A. Is the effi cacy of sorafenib
17. Montella L, Addeo R, Cennamo G, Vincenzi B, Palmieri R, treatment in patients with hepatocellular carcinoma affected by age?
Expert Rev Anticancer Ther 2013;13:1355-61.
Sperlongano P, Sperlongano R, Iodice P, Russo P, Del Prete S. Sorafenib
in elderly patients with advanced hepatocellular carcinoma: a case series.
Oncology 2013;84:265-72. How to cite this article: Giuseppe L, Alessandro V, Lonardi S,
18. Francini E, Bianco V. Tolerability of single-agent sorafenib in the Luisa B, Ardi P, Valentina M, Gino C, Camillo A, Umberto C, Vittorina Z.
Hepatocellular carcinoma in elderly patients: a concise review on systemic
treatment of elderly patients with hepatocellular carcinoma (HCC). therapy with sorafenib. Hepatoma Res 2015;1:58-62.
Hepatology 2014;60:764-5.
19. Morimoto M, Numata K, Kondo M, Hidaka H, Takada J, Shibuya A,
Kobayashi S, Ohkawa S, Okuse C, Morita S, Taguri M, Tanaka K. Higher Source of Support: Nil. Confl ict of Interest: None declared.

62 Hepatoma Research | Volume 1 | Issue 2 | July 15, 2015